Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Journal of Infectious Diseases

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/INFDIS/155.1.93PMID 3540140
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The nationwide nosocomial infection rate. A new need for vital statistics.

  1985cited by this paper
• Risk factors for nephrotoxicity in patients treated with aminoglycosides.

  1984cited by this paper
• Serum bactericidal activity of aztreonam, cefoperazone, and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa

  1984cited by this paper
• Cefotaxime compared with nafcillin plus tobramycin for serious bacterial infections. A randomized, double-blind trial.

  1984cited by this paper
• The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

  1984cited by this paper
• Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia.

  1984cited by this paper
• Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia.

  1984cited by this paper
• The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis.

  1983cited by this paper
• Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy.

  1983cited by this paper
• Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients

  1980cited by this paper
• Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin.

  1980cited by this paper
• Cephalothin plus an aminoglycoside is more nephrotoxic than methicillin plus an aminoglycoside.

  1978cited by this paper
• Controlled comparison of amikacin and gentamicin.

  1977cited by this paper
• Simultaneous antibiotic levels in "breakthrough" gram-negative rod bacteremia.

  1976cited by this paper
• Amikacin therapy for severe gram-negative sepsis. Emphasis on infections with gentamicin-resistant organisms.

  1975cited by this paper
• Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections.

  1974cited by this paper
• Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report.

  1974cited by this paper
• Experience in Monitoring Gentamicin Therapy during Treatment of Serious Gram-Negative Sepsis

  1974cited by this paper
• Gentamicin therapy in renal failure: a nomogram for dosage.

  1972cited by this paper
• A rapid chemical assay for gentamicin.

  1972cited by this paper
• Rapid evaluation of creatinine clearance.

  1971cited by this paper
• Gram-Negative Bacteremia. II. Clinical, Laboratory, and Therapeutic Observations.

  1962cited by this paper

• Circadian considerations in antimicrobials

  2026cites this paper
• Population pharmacokinetics of amikacin in patients with a haematological disorder: a prospective, observational study.

  2026cites this paper
• Uncertainty undermines the validity of antimicrobial pharmacodynamics

  2026cites this paper
• Amikacin dosing and therapeutic drug monitoring: a single tertiary centre quality improvement audit

  2026cites this paper
• Nomograms for Therapeutic Drug Monitoring of High-Dose Amikacin in Critically Ill Patients: Insights from a Population Pharmacokinetic Analysis and Dosing Simulation.

  2026cites this paper
• Microbiological and in vitro degradation response of a magnesium alloy with new surface functionalization for use as temporary bone implants

  2025cites this paper
• A Quantitative Examination and Comparison of the Ability of Australian Gentamicin Dosing Guidelines to Achieve Target Therapeutic Concentrations in Neonates

  2025cites this paper
• Feasibility of amikacin antimicrobial intravenous regional limb perfusion in canine pelvic limbs.

  2025cites this paper
• Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk

  2025cites this paper
• Rapid LAMP-Based Detection of A. baumannii and Aminoglycoside Resistance Genes in ESKAPE Pathogens.

  2025cites this paper
• PK/PD-Guided Strategies for Appropriate Antibiotic Use in the Era of Antimicrobial Resistance

  2025cites this paper
• Factors associated with elevated gentamicin trough levels in neonates: a retrospective analysis of dosing and clinical parameters

  2025cites this paper
• Amikacin dosing in neonates: evaluation of target attainment using a simplified and complex pharmacokinetic model-derived dosing regimen in clinical practice

  2025cites this paper
• Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study

  2025influential citation
• Renal Impact of a High-Loading Dose of Amikacin in Critically Ill Patients

  2025cites this paper
• Utility of a commercially available transwell system for assessment of MSC-mediated mitigation of biofilms.

  2025cites this paper
• A Bayesian Framework for Optimizing Amikacin Therapy in Critically Ill Patients With Cancer.

  2025cites this paper
• The effect of pulsatile lavage on antibiotic elution from bone cements in two-stage revision for periprosthetic joint infection

  2025influential citation
• Comparing two-sample log-linear exposure estimation with Bayesian model-informed precision dosing of tobramycin in adult patients with cystic fibrosis

  2025cites this paper
• Antimicrobial pharmacokinetics and stewardship in critically Ill adult patients receiving ECMO: Challenges, evidence, and future directions

  2025cites this paper
• Concurrent intravenous regional limb perfusion and systemic amikacin administration achieves variable synovial fluid amikacin concentrations in healthy neonatal foals.

  2025cites this paper
• Different methods of perfusate administration do not have an effect on synovial concentrations of amikacin following intravenous regional limb perfusion.

  2025cites this paper
• Recommended gentamicin peak plasma levels rarely reached, even with recommended dosages.

  2025cites this paper
• Tuning Pluronic Hydrogel Networks: Effects of Vancomycin Loading on Gelation, Rheological Properties, and Micellar Structures

  2025cites this paper
• Equine bone marrow-derived mesenchymal stromal cells reduce established S. aureus and E. coli biofilm matrix in vitro

  2024cites this paper
• The Effect of a Single-Dose Aminoglycoside With a Beta-Lactam for the Treatment of Gram-Negative Bacteremia

  2024cites this paper
• A phase I clinical study: evaluation of safety, tolerability, and population pharmacokinetic-pharmacodynamic target attainment analysis of etimicin sulfate among healthy Chinese participants.

  2024cites this paper
• Treatment of Complicated Gram-Positive Bacteremia and Infective Endocarditis

  2024cites this paper
• Effect of topical gentamicin in preventing surgical site infection in elective incisional hernia repair in a randomized controlled trial

  2024cites this paper
• Morphine synovial fluid concentrations after intravenous regional limb perfusion in horses during standing sedation.

  2024cites this paper
• Prediction of tissue exposures of polymyxin-B, amikacin and sulbactam using physiologically-based pharmacokinetic modeling

  2024cites this paper
• Pharmacokinetic and Pharmacodynamic Approaches to Optimize Antibiotic Use in Neonates.

  2024cites this paper
• Pharmacokinetics of amikacin after intravenous, intra‐articular, and combined intravenous and intra‐articular administration in healthy neonatal foals

  2024cites this paper
• Faster perfusate instillation time results in more systemic leakage of amikacin sulfate when performing intravenous regional limb perfusion in horses.

  2024cites this paper
• Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence

  2024cites this paper
• Necessity of Tobramycin trough Levels in Once Daily Iv-Treatment in Patients with Cystic Fibrosis

  2024cites this paper
• Clinical evaluation of the BioFire Respiratory Pathogen Panel for the guidance of empirical antimicrobial therapy in critically ill patients with hospital-acquired pneumonia: a multicenter, quality improvement project.

  2024cites this paper
• Comparative simulation of intraperitoneal aminoglycoside regimens for patients with peritonitis on automated peritoneal dialysis

  2024cites this paper
• Three-minute nebulization of gentamicin in healthy dogs results in therapeutic concentrations in bronchoalveolar lavage fluid while remaining below the toxic range values in blood.

  2024cites this paper
• Serum amikacin concentrations in dogs with naturally occurring open wounds treated with topical amikacin in carboxymethylcellulose hydrogel

  2024cites this paper
• International survey of antibiotic dosing and monitoring in adult intensive care units

  2023cites this paper
• Intranasal and Serum Gentamicin Concentration: Comparison of Three Topical Administration Protocols in Dogs

  2023influential citation
• Aminoglycosides for the Treatment of Severe Infection Due to Resistant Gram-Negative Pathogens

  2023cites this paper
• Effects of a 10% dimethyl sulfoxide solution on radiocarpal joint amikacin pharmacokinetics during intravenous regional limb perfusion in standing sedated horses.

  2023cites this paper
• Optimal Therapeutic Drug Monitoring Strategy for IV Aminoglycosides and IV Vancomycin in People with Cystic Fibrosis: A Systematic Review.

  2023cites this paper
• Successful Treatment of a Case of Metallo-Beta-Lactamase-Producing Raoultella ornithinolytica Bacteremia by Antimicrobial Stewardship Team Intervention and Therapeutic Drug Monitoring-Based Amikacin Treatment

  2023cites this paper
• A multifaceted strategy to optimize pharmacokinetics of antimicrobial therapy in patients with hospital-acquired infections-a monocentre quality improvement project.

  2023cites this paper
• Optimization of Antimicrobial Stewardship Programs Using Therapeutic Drug Monitoring and Pharmacokinetics–Pharmacodynamics Protocols: A Cost-Benefit Review

  2023cites this paper
• Development of a Predictive Dosing Nomogram to Achieve PK/PD Targets of Amikacin Initial Dose in Critically Ill Patients: A Non-Parametric Approach

  2023cites this paper
• Evaluation of Dosing Guidelines for Gentamicin in Neonates and Children

  2023cites this paper
• Inoculum-Based Dosing: A Novel Concept for Combining Time with Concentration-Dependent Antibiotics to Optimize Clinical and Microbiological Outcomes in Severe Gram Negative Sepsis

  2023cites this paper
• Aminoglycoside uptake, stress, and potentiation in Gram-negative bacteria: new therapies with old molecules

  2023cites this paper
• Targeting Lower Serum Trough Concentrations: A New Gentamicin Dosing Strategy for Suspected Neonatal Early-Onset Sepsis.

  2023cites this paper
• Distribution of Candida infections in patients and evaluation of the synergic interactions of some drugs against emerging fluconazole- and caspofungin-resistant C. auris

  2023cites this paper
• Towards Translation of PqsR Inverse Agonists: From In Vitro Efficacy Optimization to In Vivo Proof‐of‐Principle

  2023cites this paper
• Pragmatic physiologically-based pharmacokinetic modeling to support clinical implementation of optimized gentamicin dosing in term neonates and infants: proof-of-concept

  2023cites this paper
• Development and validation of a rabbit model of Pseudomonas aeruginosa non-ventilated pneumonia for preclinical drug development

  2023cites this paper
• Use of therapeutical apheresis methods in ICU.

  2023cites this paper
• Aminoglycosides: single- or multiple-daily dosing? An updated qualitative systematic review of randomized trials on toxicity and efficacy.

  2023cites this paper
• Development and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment

  2023cites this paper
• Development and Evaluation of a Height-Based Tobramycin Initial Dosing Nomogram for the Treatment of Adult Cystic Fibrosis Pulmonary Exacerbations

  2022cites this paper
• Gentamicin Administration in Dialysis Patients: Before or After Hemodialysis?

  2022cites this paper
• When and How to Use MIC in Clinical Practice?

  2022cites this paper
• Risk Factors Associated with Suboptimal Tobramycin Levels in the Medical Intensive Care Unit

  2022cites this paper
• How to Manage Pseudomonas aeruginosa Infections.

  2022cites this paper
• Aminoglycoside Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy

  2022cites this paper
• Population Pharmacokinetics of Orally Administered Clindamycin to Treat Prosthetic Joint Infections: A Prospective Study

  2022cites this paper
• A Systematic Review of the Effect of Therapeutic Drug Monitoring on Patient Health Outcomes during Treatment with Carbapenems

  2022cites this paper
• Systematic review of high-dose amikacin regimens for the treatment of Gram-negative infections based on EUCAST dosing recommendations

  2022cites this paper
• Empirical Antibiotic Therapy for Gram-Negative Bacilli Ventilator-Associated Pneumonia: Observational Study and Pharmacodynamic Assessment

  2022cites this paper
• Therapeutisches Drugmonitoring und pharmakokinetische Modelle als Strategie zur rationalen Antibiotikatherapie bei IntensivpatientInnen

  2022cites this paper
• Antimicrobial Treatment Options for Difficult-to-Treat Resistant Gram-Negative Bacteria Causing Cystitis, Pyelonephritis, and Prostatitis: A Narrative Review

  2022cites this paper
• Effects of regional limb perfusion technique on concentrations of antibiotic achieved at the target site: A meta-analysis

  2022cites this paper
• Therapeutic drug monitoring of Amikacin in hospitalized patients: A pilot study.

  2022cites this paper
• Increasing tourniquet number has no effect on amikacin concentration within the radiocarpal joint in horses undergoing intravenous regional limb perfusion.

  2022cites this paper
• Amikacin Therapy in Japanese Pediatric Patients: Narrative Review

  2022cites this paper
• Aminoglycosides’ dosing and monitoring practices in critically ill patients in Quebec hospitals

  2022cites this paper
• PK/PD guided gentamicin dosing in critically ill patients: a revisit of the Hartford nomogram.

  2022cites this paper
• Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.

  2022cites this paper
• Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Renal Impairment

  2022cites this paper
• Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review

  2022influential citation
• Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range

  2021cites this paper
• Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review

  2021cites this paper
• Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis

  2021cites this paper
• A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients.

  2021cites this paper
• Aminoglycoside Antibiotics

  2021cites this paper
• Gentamicin Population Pharmacokinetics in Pediatric Patients—A Prospective Study with Data Analysis Using the saemix Package in R

  2021cites this paper
• Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis

  2021cites this paper
• Involvement of oxidative stress and toll-like receptor-4 signaling pathways in gentamicin-induced nephrotoxicity in male Sprague Dawley rats

  2021cites this paper
• Therapeutic Drug Monitoring of Antimicrobial Drugs in Neonates: An Opinion Article

  2021cites this paper
• Evaluation of poly (ethylene glycol–propylene glycol) copolymer bone hemostatic agent containing gentamicin for enhancing local antibacterial and anti-inflammatory effects in an infected calvarial defect rat model

  2021cites this paper
• Gentamicin Dosing in Neonates with Normal Renal Function: Trough and Peak Levels

  2021cites this paper
• Aminoglycoside prescription: compliance with national guidelines in a pediatric hospital.

  2021cites this paper
• Optimizing Antimicrobial Drug Dosing in Critically Ill Patients

  2021cites this paper
• Decreased neutrophil‐mediated bacterial killing in COVID‐19 patients

  2021cites this paper
• Orthopedic Infections-Clinical Applications of Intravenous Regional Limb Perfusion in the Field.

  2021cites this paper
• Overcoming reduced antibiotic susceptibility in intracellular Salmonella enterica serovar Typhimurium using AR-12.

  2021cites this paper
• Assessment of the Effects of a High Amikacin Dose on Plasma Peak Concentration in Critically Ill Children

  2021cites this paper
• Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis

  2021cites this paper
• Population Pharmacokinetic Modeling and Dosing Simulations of Tobramycin in Pediatric Patients with Cystic Fibrosis

  2021cites this paper